FIZE Medical
Caesarea, Israel· Est.
AI‑driven continuous urine output monitoring to enable early AKI detection and optimized fluid management.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven continuous urine output monitoring to enable early AKI detection and optimized fluid management.
Critical CareNephrologyFluid Management
Technology Platform
Continuous digital urine output monitoring with AI‑driven analytics and EMR integration for real‑time kidney function assessment.
Opportunities
Scaling across US, EU, and Asian ICU markets; leveraging CMS AKI quality metrics; expanding AI analytics as a service for broader renal monitoring.
Risk Factors
Hospital IT integration challenges; competition from other continuous urine monitoring devices; need for extensive clinical evidence to drive adoption.
Competitive Landscape
Competes with RenalSense, Accuryn, and other continuous urine output monitors; differentiates through AI‑driven predictive alerts, seamless EMR integration, and a focus on both adult and pediatric populations.